SA has accepted an offer of just over R520-million from the Global Fund to Fight Aids, TB and Malaria to buy the twice-a-year ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or "the Company") (NASDAQ: GILD) ...

Buying $100 In GILD: If an investor had bought $100 of GILD stock 15 years ago, it would be worth $681.19 today based on a price of $112.09 for GILD at the time of writing.

The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV ...

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food and Drug Administration last month. Gilead Sciences’ lenacapavir is so effec ...

Trainer finished as a first-team player in both the KMAC and Central District and also was named a Division VI third-team ...

Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...

In January, the US stopped a planned $4 billion in global HIV funding as US President Donald Trump suspended foreign aid and moved to shut down the US Agency for International Development (USAID).

For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer ...

Thanks to a landmark deal announced on July 9 by the Global Fund, Uganda is expected to be among the first countries in sub-Saharan Africa to get access to Lenacapavir, a revolutionary new drug that ...